SCHEMBL26277080

SCHEMBL26277080

CCCCCCCCCCCCCCCCCCOC(=O)[C@H](C)NP(=O)(Oc1ccccc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.46
▸ MAPT P10636 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ CRHBP P24387 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ CES2 O00748 1/20 0.40
▸ CES1 P23141 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26277063 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL26277120 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL26277058 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL26277070 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL28854876 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL28854978 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL28855001 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL28854836 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL28854955 1.00 MGLL (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP
SCHEMBL20059145 0.97 ALDH1A1 (0.46) MGLLMAPTL3MBTL1ALDH1A1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
EP-4106877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 — — EP disclosed
US-20220356196-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2022-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 MGLL 1257/4885MAPT 2729/4885L3MBTL1 2111/4885
US-20220356196-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 MGLL 1257/4885MAPT 2729/4885L3MBTL1 2111/4885
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 MGLL 1980/4885MAPT 4373/4885L3MBTL1 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback